A 24-week randomised, double-blind, parallel-group, multi-centre, active-controlled (metformin or metformin combined with fenofibrate) study to evaluate the lipid metabolic effects, safety and tolerability of tesaglitazar [Galida (Tm)] therapy in patients with type 2 diabetes and low HDL-cholesterol on fixed background therapy with a statin.

Trial Profile

A 24-week randomised, double-blind, parallel-group, multi-centre, active-controlled (metformin or metformin combined with fenofibrate) study to evaluate the lipid metabolic effects, safety and tolerability of tesaglitazar [Galida (Tm)] therapy in patients with type 2 diabetes and low HDL-cholesterol on fixed background therapy with a statin.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Fenofibrate; Metformin; Tesaglitazar
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms GALLANT-14
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Nov 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 08 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top